Technology area: Biotechnology & Pharmaceuticals
51 pending office actions • 30 art units • 48 examiners • 0 of 51 (0%) have an AI response strategy ready • 40 patents granted in the last 365 days
Pfizer Inc. has 51 pending office actions in Biotechnology & Pharmaceuticals. The matters span 48 examiners and 30 art units, indicating a large docket with extensive examiner dispersion and repeated activity across multiple art units.
VAJDA, KRISTIN ANN is the busiest examiner, with 2 pending matters. That limited concentration means the docket is not organized around one dominant examiner, even though a small amount of examiner-level repetition exists. The difference between the number of pending matters and the number of examiners shows that most examiner relationships are matter-specific, while the art-unit distribution supports coordinated review of recurring technical and procedural issues.
Based on the USPTO statutory response window for each pending office action. 14 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 14 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 7 (14%) |
| §103 only | 8 (16%) |
| §112 only | 8 (16%) |
| Double-patenting only | 2 (4%) |
| Double-patenting + other | 6 (12%) |
| Multi-statute (no §101) | 17 (33%) |
| No statute on record | 3 (6%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| VAJDA, KRISTIN ANN | 2 | 83.8% | +11.1% |
| GANGLE, BRIAN J | 2 | 76.8% | +14.6% |
| BORALSKY, LUKE ALAN | 2 | 66.7% | +44.4% |
| MASTERS, KRISTEN MICHELLE | 1 | 65.5% | +20.6% |
| WELLS, LAUREN QUINLAN | 1 | 49.4% | +59.7% |
| KIFLE, BRUCK | 1 | 79.3% | +15.8% |
| KIM, SAMUEL CHONG | 1 | 49.2% | +69.8% |
| ZOU, NIANXIANG | 1 | 64.0% | +25.0% |
| MPAMUGO, CHINYERE | 1 | 28.9% | +26.9% |
| SHAMEEM, GOLAM M | 1 | 86.7% | +15.9% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18789272 | SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | VAJDA, KRISTIN ANN | — |
| 18719456 | COMBINATION THERAPIES AND USES FOR TREATING CANCER | SHAMEEM, GOLAM M | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17431462 | Methods for purifying bacterial polysaccharides | CREWS, JARET JAMES | 53d overdue |
| 18565626 | METHODS OF TREATMENT | VALENROD, YEVGENY | 17d overdue |
| 18557987 | VACCINATION AGAINST BACTERIAL AND BETACORONAVIRUS INFECTIONS | FOLEY, SHANON A | 8d |
| 18551038 | PHARMACEUTICAL COMPOSITIONS CONTAINING ADENO-ASSOCIATED VIRAL VECTOR | VIVLEMORE, TRACY ANN | 9d |
| 19196858 | METHOD AND APPARATUS FOR IMPROVED MAN-MACHINE INTERACTIONS | MASTERS, KRISTEN MICHELLE | — |
| 19023946 | Benzodiazepine Pyrazolo Carboxamides as N-protein Inhibitors | WELLS, LAUREN QUINLAN | — |
| 18842257 | COMPUTERIZED DECISION SUPPORT TOOL AND MEDICAL DEVICE FOR RESPIRATORY CONDITION MONITORING AND CARE | KIM, SAMUEL CHONG | — |
| 18833823 | CORONAVIRUS ANTIGEN VARIANTS | ZOU, NIANXIANG | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19196858 | METHOD AND APPARATUS FOR IMPROVED MAN-MACHINE INTERACTIONS | MASTERS, KRISTEN MICHELLE | — |
| 19023946 | Benzodiazepine Pyrazolo Carboxamides as N-protein Inhibitors | WELLS, LAUREN QUINLAN | — |
| 18954736 | Crystalline form of (2R)-2-(5-fluoro-2-methoxypyridin-4-yl)-1-[(2S)-7-methyl-6-(pyrimidin-2-yl)-3,4-dihydro-1H-spiro[1,8-naphthyridine-2,3-pyrrolidin]-1-yl]propan-1-one | KIFLE, BRUCK | — |
| 18842257 | COMPUTERIZED DECISION SUPPORT TOOL AND MEDICAL DEVICE FOR RESPIRATORY CONDITION MONITORING AND CARE | KIM, SAMUEL CHONG | — |
| 18789272 | SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | VAJDA, KRISTIN ANN | — |
| 18833823 | CORONAVIRUS ANTIGEN VARIANTS | ZOU, NIANXIANG | — |
| 18722084 | DIGITAL MEDICINE COMPANION FOR TREATING AND MANAGING SKIN DISEASES | MPAMUGO, CHINYERE | — |
| 18719456 | COMBINATION THERAPIES AND USES FOR TREATING CANCER | SHAMEEM, GOLAM M | — |
| Art Unit | Apps |
|---|---|
| 1624 | 5 |
| 1645 | 4 |
| 1622 | 3 |
| 1671 | 3 |
| 1691 | 3 |
| 3791 | 2 |
| 1629 | 2 |
| 1674 | 2 |
| 1621 | 2 |
| 1626 | 2 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19196858 | METHOD AND APPARATUS FOR IMPROVED MAN-MACHINE INTERACTIONS | MASTERS, KRISTEN MICHELLE | 2659 | §101§103 | Non-Final OA | — | Pending | May 02, 2025 |
| 19023946 | Benzodiazepine Pyrazolo Carboxamides as N-protein Inhibitors | WELLS, LAUREN QUINLAN | 1622 | §103§112Other | Non-Final OA | — | Pending | Jan 16, 2025 |
| 18954736 | Crystalline form of (2R)-2-(5-fluoro-2-methoxypyridin-4-yl)-1-[(2S)-7-methyl-6-(pyrimidin-2-yl)-3,4-dihydro-1H-spiro[1,8-naphthyridine-2,3-pyrrolidin]-1-yl]propan-1-one | KIFLE, BRUCK | 1624 | DP | Non-Final OA | — | Pending | Nov 21, 2024 |
| 18842257 | COMPUTERIZED DECISION SUPPORT TOOL AND MEDICAL DEVICE FOR RESPIRATORY CONDITION MONITORING AND CARE | KIM, SAMUEL CHONG | 3791 | §101§103§112 | Non-Final OA | — | Pending | Aug 28, 2024 |
| 18789272 | SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | VAJDA, KRISTIN ANN | 1624 | DP | Non-Final OA | — | Pending | Jul 30, 2024 |
| 18833823 | CORONAVIRUS ANTIGEN VARIANTS | ZOU, NIANXIANG | 1671 | §101§102§103 | Non-Final OA | — | Pending | Jul 26, 2024 |
| 18722084 | DIGITAL MEDICINE COMPANION FOR TREATING AND MANAGING SKIN DISEASES | MPAMUGO, CHINYERE | 3685 | §101§103 | Non-Final OA | — | Pending | Jun 20, 2024 |
| 18719456 | COMBINATION THERAPIES AND USES FOR TREATING CANCER | SHAMEEM, GOLAM M | — | §112 | Non-Final OA | — | Pending | Jun 13, 2024 |
| 18739401 | POLYNUCLEOTIDE COMPOSITIONS AND USES THEREOF | OGUNBIYI, OLUWATOSIN A | 1645 | §102§103§112 | Non-Final OA | — | Pending | Jun 11, 2024 |
| 18714642 | CDK4 INHIBITOR FOR THE TREATMENT OF CANCER | TOWNSLEY, SARA ELIZABETH | 1629 | §103§112DP | Non-Final OA | — | Pending | May 30, 2024 |
| 18708093 | Enhancement Of CD47 Blockade Therapy With Anti-VEGF Agents | HOLTZMAN, KATHERINE ANN | 1646 | §101§102§103§112DP | Non-Final OA | — | Pending | May 07, 2024 |
| 18706732 | METHODS OF TREATING MITOCHONDRIAL MYOPATHIES USING ANTI-GDF15 ANTIBODIES | ABBAS, SYED JARAR | 1674 | §103§112DP | Non-Final OA | — | Pending | May 01, 2024 |
| 18621962 | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof | GANGLE, BRIAN J | 1691 | §102§112DP | Non-Final OA | — | Pending | Mar 29, 2024 |
| 18249752 | METHODS FOR MEASURING DYSTROPHIN IN TISSUE SAMPLES | SODERQUIST, ARLEN | 1797 | §102§103§112 | Non-Final OA | — | Pending | Feb 28, 2024 |
| 18586896 | CETYLTRIMETHYLAMMONIUM BROMIDE (CTAB) AS A LYSIS AND FLOCCULATION REAGENT IN GENE THERAPY DOWNSTREAM PROCESSES | KARUNASENA, ENUSHA | 1653 | §102§103§112 | Non-Final OA | — | Pending | Feb 26, 2024 |
| 18684225 | Amorphous Form of (S)-2-(5-((3-Ethoxypyridin-2-YL)Oxy)Pyridin-3-YL)-N-(Tetrahydrofuran-3-YL)Pyrimidine-5-Carboxamide | YOO, SUN JAE | 1621 | §112 | Non-Final OA | — | Pending | Feb 16, 2024 |
| 18541015 | HSD17B13 Inhibitors and/or Degraders | BORALSKY, LUKE ALAN | 1624 | §102§103§112 | Non-Final OA | — | Pending | Dec 15, 2023 |
| 18535116 | IMMUNOGENIC COMPOSITIONS AND METHODS FOR ELICITING AN IMMUNE RESPONSE AGAINST CLOSTRIDIOIDES (CLOSTRIDIUM) DIFFICILE | HAUK TEODORO, PRICILA NMN | 1645 | §103DP | Final Rejection | 34d | Pending | Dec 11, 2023 |
| 18532424 | Papain-like protease (PLpro) inhibitors | BELL, SARA ELIZABETH | 1625 | §102§112 | Non-Final OA | — | Pending | Dec 07, 2023 |
| 18557987 | VACCINATION AGAINST BACTERIAL AND BETACORONAVIRUS INFECTIONS | FOLEY, SHANON A | 1671 | §103§112 | Final Rejection | 8d | Pending | Oct 30, 2023 |
| 18552453 | Ether-Linked Antiviral Compounds | ANDERSON, REBECCA L | 1626 | §112 | Non-Final OA | 71d overdue | Pending | Sep 26, 2023 |
| 18551619 | METHODS FOR PRODUCING OF LIPIDS | CARR, DEBORAH D | 1691 | §103§112 | Non-Final OA | — | Pending | Sep 21, 2023 |
| 18551038 | PHARMACEUTICAL COMPOSITIONS CONTAINING ADENO-ASSOCIATED VIRAL VECTOR | VIVLEMORE, TRACY ANN | 1638 | §102§103§112Other | Non-Final OA | 9d | Pending | Sep 18, 2023 |
| 18550326 | Methods For Treatment of Vitiligo | FERGUSON, JALISA HOLMES | 1626 | §102§103§112 | Non-Final OA | — | Pending | Sep 13, 2023 |
| 18549158 | Treatment of Breast Cancer with Amcenestrant and Palbociclib | LEESER, ERICH A | 1622 | §103 | Non-Final OA | 22d | Pending | Sep 05, 2023 |
| 18277425 | NOVEL DRUGGABLE REGIONS IN THE HUMAN CYTOMEGALOVIRUS GLYCOPROTEIN B POLYPEPTIDE AND METHODS OF USE THEREOF | CORNELIUS, CLAIRE ADRIENNE | 1618 | §101§102§112 | Non-Final OA | — | Pending | Aug 16, 2023 |
| 18446883 | COMPOSITIONS AND METHODS FOR ELICITING AN IMMUNE RESPONSE AGAINST CLOSTRIDIUM DIFFICILE | GANGLE, BRIAN J | 1645 | §103§112 | Non-Final OA | — | Pending | Aug 09, 2023 |
| 18350986 | CELLS AND METHOD OF CELL CULTURE | HUMPHRIES, NICHOLAS ADAM | 1631 | §103 | Final Rejection | 60d overdue | Pending | Jul 12, 2023 |
| 18343968 | NEISSERIA MENINGITIDIS COMPOSITIONS AND METHODS THEREOF | DEVI, SARVAMANGALA | 1645 | — | Final Rejection | — | Pending | Jun 29, 2023 |
| 18268959 | SOLID FORMS OF A CDK2 INHIBITOR | MCDOWELL, BRIAN E | 1624 | §112 | Final Rejection | — | Pending | Jun 21, 2023 |
| 18258027 | IMPROVED PHARMACEUTICAL COMPOSITIONS CONTAINING ADENO-ASSOCIATED VIRAL VECTOR | RIGA, MICHAEL ANGELO | 1634 | §102§103§112 | Non-Final OA | — | Pending | Jun 16, 2023 |
| 18257215 | HILIC UPLC-MS Method For Separating and Analyzing Intact Adeno-Associated Virus Capsid Proteins | LY, KRISTINA ELISABETH | 1671 | §103§112 | Non-Final OA | — | Pending | Jun 13, 2023 |
| 18249581 | PEG-FREE AQUEOUS SUSPENSIONS FOR PARENTERAL ADMINISTRATION OF A CORTICOSTEROID | AGGARWAL, SAHIL CHANDER | 1623 | §103 | Non-Final OA | — | Pending | Apr 19, 2023 |
| 18249411 | Methods for purifying bacterial polysaccharides | PATEL, PRANAV N | 1777 | §112 | Final Rejection | 29d | Pending | Apr 18, 2023 |
| 18041447 | Methods of Protecting RNA | BATES, KEENAN ALEXANDER | 1631 | §112 | Final Rejection | — | Pending | Feb 13, 2023 |
| 18146014 | COMBINATION OF AN ANTI-PD-L1 ANTIBODY AND A DNA-PK INHIBITOR FOR THE TREATMENT OF CANCER | JOHANSEN, PETER N. | 1644 | §103DP | Non-Final OA | 85d overdue | Pending | Dec 23, 2022 |
| 18002555 | COMPUTERIZED DECISION SUPPORT TOOL AND MEDICAL DEVICE FOR SCRATCH DETECTION AND FLARE PREDICTION | WESTFALL, SARAH ANN | 3791 | §103 | Non-Final OA | — | Pending | Dec 20, 2022 |
| 18002368 | METHOD OF TREATMENT OF INFLAMMATORY BOWEL DISEASE USING ANTI-TL1A ANTIBODIES | KAUFMAN, CLAIRE M | 1674 | §103§112 | Non-Final OA | — | Pending | Dec 19, 2022 |
| 17997312 | MODIFIED NUCLEIC ACIDS ENCODING ASPARTOACYLASE (ASPA) AND VECTOR FOR GENE THERAPY | ALLEN, SARAH ELIZABETH | 1637 | Other | Non-Final OA | 34d | Pending | Oct 27, 2022 |
| 17799992 | PURIFICATION OF SACCHARIDES | LAU, JONATHAN S | 1693 | §102§103 | Final Rejection | — | Pending | Aug 16, 2022 |
| 17607341 | REAL-TIME TRACKING AND MANAGEMENT OF STANDARD WORKFLOWS | KONERU, SUJAY | 3624 | §101§103 | Non-Final OA | — | Pending | Oct 28, 2021 |
| 17431462 | Methods for purifying bacterial polysaccharides | CREWS, JARET JAMES | 1691 | §103§112 | Final Rejection | 53d overdue | Pending | Aug 17, 2021 |
| 19024658 | METHOD OF TREATING CONDITIONS RELATED TO THE PGI2 RECEPTOR | VAJDA, KRISTIN ANN | — | Other | Non-Final OA | — | Pending | Jan 16, 2025 |
| 18841455 | NOVEL S1P1 RECEPTOR AGONIST, CRYSTALLINE SALTS, PROCESSES FOR PREPARING, AND USES RELATED THERETO | AULAKH, CHARANJIT | 1621 | §112 | Final Rejection | — | Pending | Aug 26, 2024 |
| 18441209 | MODULATORS OF THE PROSTACYCLIN (PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | SAWYER, JENNIFER C | 1658 | §112 | Non-Final OA | — | Pending | Feb 14, 2024 |
| 18566862 | Administration of a Compound to Individuals with Hepatic Impairment | TRAN, ERIC | 1629 | §103Other | Non-Final OA | 12d | Pending | Dec 04, 2023 |
| 18565626 | METHODS OF TREATMENT | VALENROD, YEVGENY | 1628 | §103§112 | Final Rejection | 17d overdue | Pending | Nov 30, 2023 |
| 18259843 | Methods of Treatment | ABDALHAMEED, MANAHIL MIRGHANI ALI | 1622 | §103Other | Non-Final OA | 71d | Pending | Jun 29, 2023 |
| 18830475 | TABLETS COMPRISING 2-HYDROXY-6-((2-(1-ISOPROPYL-1H-PYRAZOL-5-YL)PYRIDIN-3-YL)METHOXY)BENZALDEHYDE | BAEK, BONG-SOOK | 1611 | §103Other | Non-Final OA | — | Pending | Sep 10, 2024 |
| 18717181 | METHODS OF ADMINISTERING A MODULATOR OF HEMOGLOBIN | BORALSKY, LUKE ALAN | 1624 | §102§103§112DP | Non-Final OA | — | Pending | Jun 06, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialPfizer Inc. has 51 pending office actions as of October 2026, spread across 30 art units and 48 examiners.
Kristin Ann Vajda has the most, with 2 of Pfizer Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
